Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$42.24

-0.92 (-2.13%)

04:55
05/19/17
05/19
04:55
05/19/17
04:55

Ionis Pharmaceuticals management to meet with Needham

Meetings to be held in Boston on May 18 and in New York on May 19 hosted by Needham.

  • 19

    May

  • 24

    May

IONS Ionis Pharmaceuticals
$42.24

-0.92 (-2.13%)

05/16/17
RHCO
05/16/17
NO CHANGE
RHCO
Prothena has positive read through from Ionis safety issues, says SunTrust
SunTrust analyst Yun Zhong says that safety issues with Ionis' inotersen during a Phase III trial are positive for Prothena. The analyst says that Prothena's new drug, PRX004, could have a better safety profile than its previous drug, NEOD001,. He notes that PRX004 has a different mechanism of action than Ionis' drug, and he thinks the discrepancy could enable Prthena's drug to have a better safety profile. He keeps a Buy rating on Prothena.
05/16/17
LEER
05/16/17
NO CHANGE
Target $67
LEER
Outperform
Alnylam price target raised to $67 from $53 at Leerink
Leerink analyst Paul Matteis expects yesterday's data from Ionis Pharmaceuticals (IONS) will put TTRrx at a commercial disadvantage to Alnylam's (ALNY) patisiran. The top-line results for TTRrx, which showed high efficacy and several safety issues, is the best case for Alnylam, Matteis tells investors in a research note. He raised his odds of approval for both programs but lowered his price target for Ionis to $45 from $47. Matteis has Market Perform ratings on both stocks.
05/16/17
PIPR
05/16/17
NO CHANGE
Target $69
PIPR
Overweight
Piper Jaffray sees positive readthrough for Prothena from Ionis data
Piper Jaffray analyst Steven Breazzano argues that investors should "take a closer look" at Prothena (PRTA) and its PRX004 product following the recent amyloid neuropathy data from Ionis Pharmaceuticals (IONS). Prothena's candidate is expected to enter the clinic in early 2018, and Breazzano argues that there is "room for differentiation" in the space, as the drug clears the protein buildup that characterizes amyloidosis rather than directly shutting off production, as with Ionis and Alnylam's (ALNY) approaches. "At a minimum," the analyst says, a deposit-clearing approach would be complementary to production-stopping drugs. Breazzano reiterates an Overweight rating on Prothena.
05/17/17
LTCO
05/17/17
NO CHANGE
Target $80
LTCO
Buy
Alnylam price target raised to $80 from $75 at Ladenburg
Ladenburg Thalmann analyst Christopher James raised his price target for Alnylam (ALNY) to $80 saying the NEURO-TTR data reported by Ionis Pharmaceuticals (IONS) are "quite positive" for patisiran and the upcoming APOLLO readout. The analyst reiterates a Buy rating on Alnylam shares.

TODAY'S FREE FLY STORIES

TTNP

Titan Pharmaceuticals

$1.90

-0.1 (-5.00%)

17:49
10/19/17
10/19
17:49
10/19/17
17:49
Hot Stocks
Titan Pharmaceuticals presents non-clinical data from liothyronine implant »

Titan Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$82.20

1.37 (1.69%)

17:46
10/19/17
10/19
17:46
10/19/17
17:46
Earnings
MSA Safety reports Q3 EPS 92c, consensus 80c »

Reports Q3 revenue $296M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

SKX

Skechers

$24.03

-1.06 (-4.22%)

, CAI

CAI International

$31.38

-0.05 (-0.16%)

17:41
10/19/17
10/19
17:41
10/19/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$24.03

-1.06 (-4.22%)

CAI

CAI International

$31.38

-0.05 (-0.16%)

PYPL

PayPal

$67.25

-0.01 (-0.01%)

MXIM

Maxim Integrated

$50.09

0.24 (0.48%)

IMDZ

Immune Design

$5.50

-1.05 (-16.03%)

NCR

NCR Corp.

$37.05

-0.26 (-0.70%)

TACO

Del Taco

$15.39

-0.01 (-0.06%)

ATHN

athenahealth

$116.41

-4.37 (-3.62%)

ISRG

Intuitive Surgical

$357.46

3.09 (0.87%)

ETFC

E-Trade

$43.69

-0.23 (-0.52%)

CELG

Celgene

$135.96

-1.21 (-0.88%)

PBMD

Prima BioMed

$2.36

-0.02 (-0.84%)

AAXN

Axon

$24.62

-0.37 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 29

    Nov

DGX

Quest Diagnostics

$93.23

1.18 (1.28%)

17:37
10/19/17
10/19
17:37
10/19/17
17:37
Hot Stocks
Quest Diagnostics acquires Cleveland HeartLab, terms not disclosed »

Advantage Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

AAXN

Axon

$24.62

-0.37 (-1.48%)

17:34
10/19/17
10/19
17:34
10/19/17
17:34
Hot Stocks
Axon says now aware of comment letter over SEC's review of 10-K, 10-Q »

Axon Enterprise said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMX

BioPharmX

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on BioPharmX »

BioPharmX files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$0.74

0.0248 (3.47%)

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on MabVax Therapeutics »

MabVax Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$80.15

0.05 (0.06%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Earnings
Iberiabank reports Q3 non-GAAP EPS $1.00, consensus $1.16 »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

DRRX

Durect

$1.97

0.03 (1.55%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Durect »

Durect trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCP

Quality Care Properties

$16.26

0.07 (0.43%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Quality Care Properties provides update on HCR ManorCare »

Quality Care Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTR

Frontier Communications

$11.48

0.02 (0.17%)

, CHH

Choice Hotels

$68.45

0.25 (0.37%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Frontier Communications named a Qualified Vendor with Choice Hotels Internationa »

Frontier Communications…

FTR

Frontier Communications

$11.48

0.02 (0.17%)

CHH

Choice Hotels

$68.45

0.25 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 08

    Nov

DRIO

DarioHealth

$1.98

-0.2 (-9.17%)

17:16
10/19/17
10/19
17:16
10/19/17
17:16
Syndicate
Breaking Syndicate news story on DarioHealth  »

DarioHealth files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBI

Customers Bancorp

$33.16

0.46 (1.41%)

17:11
10/19/17
10/19
17:11
10/19/17
17:11
Hot Stocks
Customers Bancorp to spin off BankMobile business »

Customers Bancorp plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 15

    Nov

MVC

MVC Capital

$10.40

0.08 (0.78%)

17:07
10/19/17
10/19
17:07
10/19/17
17:07
Hot Stocks
MVC Capital: Glass Lewis, Egan-Jones against proposal to cease new investments »

MVC Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CELG

Celgene

$135.96

-1.21 (-0.88%)

17:05
10/19/17
10/19
17:05
10/19/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Celgene »

Celgene down 6.6% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

NGD

New Gold

$3.57

0.03 (0.85%)

17:03
10/19/17
10/19
17:03
10/19/17
17:03
Hot Stocks
New Gold says Rainy River Mine achieves commercial production »

New Gold reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

COR

CoreSite Realty

$114.84

0.01 (0.01%)

17:02
10/19/17
10/19
17:02
10/19/17
17:02
Syndicate
Breaking Syndicate news story on CoreSite Realty »

CoreSite Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 13

    Nov

SXT

Sensient

$78.26

-0.43 (-0.55%)

17:02
10/19/17
10/19
17:02
10/19/17
17:02
Earnings
Breaking Earnings news story on Sensient »

Sensient backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

WHG

Westwood Holdings Group

$69.16

0.58 (0.85%)

17:01
10/19/17
10/19
17:01
10/19/17
17:01
Hot Stocks
Westwood Holdings Group settles lawsuit »

AGF, Westwood, Patricia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SXT

Sensient

$78.26

-0.43 (-0.55%)

17:01
10/19/17
10/19
17:01
10/19/17
17:01
Earnings
Sensient reports Q3 adjusted EPS 89c, consensus 88c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

GPP

Green Plains Partners

$19.50

-0.05 (-0.26%)

17:00
10/19/17
10/19
17:00
10/19/17
17:00
Hot Stocks
Green Plains Partners raises quarterly distribution 1c to 46c per unit »

Green Plains Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$135.96

-1.21 (-0.88%)

17:00
10/19/17
10/19
17:00
10/19/17
17:00
Hot Stocks
Breaking Hot Stocks news story on Celgene 

Celgene trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

NSM

Nationstar

$19.71

-0.43 (-2.14%)

16:59
10/19/17
10/19
16:59
10/19/17
16:59
Periodicals
Nationstar working with advisors on strategic options, Betaville says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLW

Clearwater Paper

16:59
10/19/17
10/19
16:59
10/19/17
16:59
Earnings
Clearwater Paper sees Q4 adjusted EPS 71c-$1.04, consensus 94c »

Sees Q4 net sales up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ISRG

Intuitive Surgical

$357.46

3.09 (0.87%)

16:58
10/19/17
10/19
16:58
10/19/17
16:58
Hot Stocks
Intuitive Surgical raises FY17 procedure growth view 15%-16% from 14%-15% »

Sees FY17 pro forma gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.